SITC2024: The paring of CD200 humanized cancer cells with CD200 and CD200R double humanized mice for the preclinical evaluation of the combination of anti-human CD200 antibodies and immune checkpoint drugs
Summary: B-hCD200/hCD200R mice express human CD200 and CD200R. B-hCD200 MC38 cells express human CD200. Tumor growth of B-hCD200 MC38 and wild-type MC38 cells was comparable…
Read more
SITC 2024: Humanized HER2-expressing tumor cells established syngeneic models for evaluating HER2 antibody-drug conjugate (ADC) therapy
Summary: B-hHER2 MC38 plus and B-hHER2 CT26.WT cell lines demonstrate overexpression of the human HER2 protein. B-hHER2 MC38 plus and B-hHER2 CT26.WT cell lines exhibit…
Read more
SITC 2024: A novel IL12Rβ1 and IL12Rβ2 humanized mouse model for preclinical efficacy and toxicity evaluation of human IL-12 analogs
Summary: Functional Analysis: Human IL-12 induced IFN-γ production in CD4+ T cells sorted from splenocytes of homozygous B-hIL12RB1/hIL12RB2 mice. In Vivo Toxicity Study: Human IL-12…
Read more
SITC 2024: Establishing a tumor cell model to evaluate the bystander effect of antibody-drug conjugate (ADC) therapies
Summary: Human TROP2 protein was not detected, but strong luminescence and GFP fluorescence were observed in B-Luc-GFP KI, TROP2 KO BxPC-3 cells. TROP2-ADC treatment led…
Read more
SITC2024: TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate development
Summary: RenMice platforms including RenMab, RenLite, RenNano with KO strategy enable accelerated identification of fully human antibodies with increased diversity of antibody paratopes and species…
Read more
SFN 2024: A novel mouse model for in vivo evaluation of anti-human CD98HC antibody penetration across blood-brain barrier
Summary: Protein expression analysis: Mouse CD98HC protein was detectable on T cells and B cells in the spleens of WT C57BL/6 mice. In contrast, human…
Read more
SFN 2024: A novel humanized TAU mouse model for preclinical development of oligonucleotide drugs for Alzheimer’s Disease
Summary: mRNA expression analysis: Mouse Mapt mRNA was detectable in wild-type C57BL/6 mice. Human MAPT mRNA was detectable in B-hTAU mice. Protein expression analysis: Human…
Read more
ASCO 2024: A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC)
Used in the poster: YH003 Poster Highlights: YH003 + Toripalimab with/without chemotherapy, as 1L or 2L+ treatment in patients with u/m PDAC have promising anti-tumor…
Read more
IO Summit Europe 2024: Fully Human Conditional Agonist 4-1BB×CD40 Bispecific Antibody Exhibits Potent In Vitro and In Vivo Efficacy
Used in the poster: BsAb Discovery Platform Summary: 4-1BB and CD40 agonists are promising candidates for cancer immunotherapy but have had limited success…
Read more
Festival of Biologics 2024: Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)
Used in the poster: Bispecific ADC Platform Summary: Biocytogen's antibody discovery team has generated a library of antibodies targeting approximately 200 tumor-associated antigens…
Read more
AACR 2024: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies
Used in the poster: TCR-Mimic Antibody Platform Summary: Novel antibodies highly specific to KRAS mutations (G12V and G12D) presented by human leukocyte antigen (HLA) were…
Read more
AACR 2024: Establishment of a humanized IL5/IL5RA mouse model to evaluate modulators of eosinophilic inflammation in vivo
Used in the poster: B-hIL5/hIL5RA mice Summary: IL-5/IL-5R signaling is crucial for eosinophil function and has therapeutic implications for inflammatory diseases like asthma. We developed…
Read more